AgingResearch.NewsJoin free

Contineum Therapeutics

CompanyUnited States

Contineum Therapeutics develops one asset, in phase 2 (PIPE-791 in idiopathic pulmonary fibrosis). Mostly small molecule acting on inflammation and LPAR1; based in the United States.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1

  • PIPE-791

    Small molecule inhibitor of lysophosphatidic acid receptor 1 (LPA1) to reduce fibrosis.

    Phase 2, Small molecule, Inflammation, LPAR1, idiopathic pulmonary fibrosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Signals1
  • Similar companies6

Intelligence